newsfilter
← Earnings
Earnings Releases·

SELLAS Life Sciences — Third Quarter 2026 Earnings Summary

  • Net loss for Q3 2026 was $10.1 million ($0.05/share), widening from $6.8 million ($0.06/share) in Q3 2025, while cash and cash equivalents rose to $134.7 million from $71.8 million at year-end 2025.
  • The Phase 3 REGAL trial for Galinpepimut-S (GPS) in AML reached its 80th event in October 2026, with top-line primary endpoint results expected in November 2026 to support a potential Biologics License Application.
  • Tambiciclib (SLS009) enrollment in newly diagnosed AML is 50% complete (40 of 80 patients), with preliminary topline data anticipated in Q4 2026, alongside positive preclinical activity in pancreatic cancer models.
  • Operating expenses increased significantly in Q3 2026, with R&D rising to $7.0 million from $4.2 million and G&A increasing to $4.3 million from $2.9 million year-over-year.
  • Management confirmed the company is well-positioned to advance clinical programs with its strengthened cash balance, noting potential transformative value for GPS in second complete remission AML patients if Phase 3 results are successful.
Company
SELLAS LIFE SCIENCES GROUP INC
Sector
Healthcare
Industry
Biotechnology